CRDL · Cardiol Therapeutics Inc.

The acceptance of Phase II MAvERIC study results for publication in the Journal of the American Heart Association (JAHA) provides independent peer-reviewed validation of CardiolRx's clinical benefits in recurrent pericarditis. The data demonstrated rapid and sustained reductions in pain and inflammation, a substantial decrease in pericarditis episodes per year, and a favorable safety profile. These findings strengthen the foundation for the ongoing pivotal Phase III MAVERIC trial, which has surpassed 75% enrollment. CardiolRx, a small-molecule inflammasome inhibitor, offers a potential non-immunosuppressive alternative to current treatments like corticosteroids and biologics, which carry significant side effects. The publication enhances the credibility of the drug candidate and supports its path toward a potential NDA submission. For investors, this milestone de-risks the Phase III program and highlights the significant unmet medical need in recurrent pericarditis, affecting approximately 40,000 patients annually in the U.S.